'Single-cycle antisense oligonucleotide delivery achieves widespread target knockdown in CNS'

Disease	Coverage Score	Rationale
ALS	10/10	Primary indication — ~20% of familial ALS driven by SOD1 mutations
FTD	4/10	Secondary — SOD1 pathology present in some FTD subtypes
AD	2/10	Minimal — Aβ toxicity unrelated to SOD1
PD	2/10	Minimal — no established SOD1 link
Aging	5/10	Moderate — SOD1 aggregation associated with age-related proteostasis decline

Dimension	Score	Rationale
Novelty	8/10	Established target (SOD1) but novel delivery modality — blood-brain barrier-crossing ASOs
Mechanistic Rationale	9/10	Strong — mutant SOD1 causes toxic gain-of-function, aggregation, mitochondrial dysfunction
Root-Cause Coverage	9/10	High — directly targets genetic cause in SOD1-ALS
Delivery Feasibility	7/10	Moderate — intrathecal delivery established (Spinraza), but AAV-CNS penetration variable
Safety Plausibility	7/10	Moderate — off-target effects possible, but ASO chemistry well-characterized
Combinability	8/10	High — combines with Riluzole, edaravone, mitochondrial protectors
Biomarker Availability	8/10	High — NfL as enrollment/response biomarker, CSF SOD1 levels as engagement marker
De-risking Path	8/10	Strong — established ASO platform, clear regulatory precedent (Spinraza)
Multi-disease Potential	4/10	Limited — primarily ALS-specific, some FTD overlap
Patient Impact	9/10	High — addresses fatal genetic subtype with no current disease-modifying therapy

¶ SOD1 Targeted RNA Silencing Therapy for ALS